Essential Hypertension
Conditions
Keywords
essential hypertension, ARB, compliance, candesartan
Brief summary
The CoCa study with at maximum daily dose of 32 mg candesartan or 16/12.5 mg candesartan/hydrochlorothiazide has the objective to evaluate under naturalistic conditions, i.e. under routine medical care conditions, the subject compliance as well as the efficacy and tolerability of candesartan or candesartan/HCT in subjects suffering from essential hypertension.
Interventions
None listed
Sponsors
AstraZeneca
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Healthy volunteers
No
Inclusion criteria
* essential hypertension * under candesartan treatment
Exclusion criteria
\-
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To estimate under naturalistic conditions the compliance rate, defined as the number of subjects with regular intake of the prescribed dose of candesartan or candesartan/HCT as judged by the physician at the end of the observational period. | app. 3 monthly |
Secondary
| Measure | Time frame |
|---|---|
| To assess under naturalistic conditions the subject's reason(s) for being compliant or non-compliant with the intake of the pre-scribed dose of candesartan or candesartan/HCT | app. 3 monthly |
| To assess under naturalistic conditions the subject's reason(s) for withdrawal of the pre-scribed dose of candesartan or candesartan/HCT | app. 3 monthly |
| To assess under naturalistic conditions whether physicians are using procedures to improve the subject's compliance regarding the intake of candesartan or candesartan/HCT and to get insight in the type and effects of these procedures | app. 3 monthly |
Outcome results
None listed